Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
Diabetes & Metabolism Journal · 2024
DOI: 10.4093/dmj.2023.0259 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes & Metabolism Journal, 2024. Verfasst von Ji-Yeon Park und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Metformin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Guidelines for switching to triple combination therapy directly after monotherapy failure are limited. This study investigated the efficacy, long-term sustainability, and safety of either mono or dual add-on therapy using alogliptin and pioglitazone for patients with type 2 diabetes mellitus (T2DM) who did not achieve their target glycemic range with metformin monotherapy.
Methods
The Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) was a multicenter, placebo-controlled, double-blind, randomized trial. A total of 214 participants were randomized to receive alogliptin+pioglitazone (Alo+Pio group, n=70), alogliptin (Alo group, n=75), or pioglitazone (Pio group, n=69). The primary outcome was the difference in glycosylated hemoglobin (HbA1c) levels between the three groups at baseline to 24 weeks. For durability, the achievement of HbA1c levels
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- MedicalExcellence Inc., Seoul, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea.
- Division of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Korea.
- Division of Endocrinology and Metabolism, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- Division of Endocrinology and Metabolism, Bundang Jesaeng Hospital, Seongnam, Korea.
Zitieren
APA
Park, J. Y., Lee, J., Choi, Y. H., Min, K. W., Han, K. A., Ahn, K. J., Lim, S., Kim, Y. H., Ahn, C. W., Choi, K. M., & Yoon, K. H. (2024). Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2023.0259
Vancouver
Park JY, Lee J, Choi YH, Min KW, Han KA, Ahn KJ, et al. Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial. Diabetes & Metabolism Journal. 2024. doi:10.4093/dmj.2023.0259
BibTeX
@article{Park2024,
author = {Park, Ji-Yeon and Lee, Joonyub and Choi, Yoon-Hee and Min, Kyung Wan and Han, Kyung Ah and Ahn, Kyu Jeung and Lim, Soo and Kim, Young-Hyun and Ahn, Chul Woo and Choi, Kyung Mook and Yoon, Kun-Ho},
title = {Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial},
journal = {Diabetes & Metabolism Journal},
year = {2024},
doi = {10.4093/dmj.2023.0259}
}
EUVIMED